Polycystic Ovary Syndrome Treatment Using DLBS3233, Metformin, and Combination of Both, and Its Relation to Fertility
Phase of Trial: Phase III
Latest Information Update: 29 May 2019
Price : $35 *
At a glance
- Drugs DLBS 3233 (Primary) ; Metformin
- Indications Insulin resistance; Polycystic ovary syndrome
- Focus Registrational; Therapeutic Use
- Acronyms POSITIF
- Sponsors Dexa Medica
- 24 May 2019 Status changed from active, no longer recruiting to completed.
- 24 Jan 2019 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 24 Jan 2019 Planned primary completion date changed from 1 Aug 2018 to 1 Feb 2019.